Henlius (2696.HK)  
1H20 Results  
Investor Presentation

August, 2020
Disclaimer

- Henlius, the representor or the provider does not make any warranties, statements or representations, express or implied, on the content of this document (the content of this document may also include forward-looking statements), including but not limited to statements about the timeliness, universality and accuracy of the content for any specific purpose or with regard to the correctness of the information obtained by using the content of this document. If any conduct or consequence is caused by any mistake, omission or incorrectness of the relevant content, Henlius, the representor or the provider shall not be liable.

- All rights, including copyrights, of this document and the content contained herein shall be exclusively owned by Henlius, among which the relevant words, patterns and logos relating to “Henlius” and “复宏汉霖” are the names, trademarks and logos legally owned by Henlius. No third-party could use them by any means, including reproduction, without written consent from Henlius.

- The content of this document does not include and shall not be deemed as any advice (including but not limited to medical advice and investment advice). You shall be liable for any decision made by yourself based on the content of this document.
Business Review

Scott Liu– CEO & Co-founder

© 2020 Henlius
**Mission and Vision**

**Mission**
To improve patients’ lives by timely providing them with quality and affordable protein therapeutics through technical innovation and operational excellence.

**Vision**
Be the most trusted and admired biotech company providing innovative and affordable medicines to all patients.

- Reliable Quality
- Affordable Innovation
- Biosimilars + Bio-innovatives + Combo
- Quality Focus · Global Footprints
Henlius Has Achieved Multiple Milestones Since 2020

- 2,000L bioreactor & 500 mg formulation approval for 汉利康® (HLX01, Rituximab)
- EMA CHMP positive opinion for HLX02 (Trastuzumab)
- EU approval for HLX02 (Trastuzumab, Zercepac®)
- China approval for HLX02 (Trastuzumab, 汉曲优®)

2020.04

- EU GMP certification for HLX02 (Trastuzumab)
- Completion of pilot plant at Songjiang Plant 1, continuous production plant under construction
- New indication approval for 汉利康® (HLX01, Rituximab) in China (follicular lymphoma and chronic lymphocytic leukemia)
- Primary endpoint reached for HLX04 (Bevacizumab) phase 3 clinical trial

2020.05

2020.07

2020.08
**The Impact of COVID-19 on Henlius Is Manageable**

<table>
<thead>
<tr>
<th>R&amp;D</th>
<th>Clinical</th>
<th>Manufacturing</th>
<th>Commercial</th>
</tr>
</thead>
</table>
| • R&D on track  
  • Started two COVID-19 projects HLX70 & HLX71 | • Limited impact on clinical trial progress (as cancer patients are less likely to avoid treatments) | • No impact on Xuhui facility  
  • Songjiang Plant 2 construction delayed for 1-2 months with possibility to catch up later on | • Limited impact on 汉利康® (HLX01, Rituximab) sales  
  • Our commercial team recruitment as planned |
**Leverage Platform Advantage, Accelerate Development of COVID-19 Drugs**  
- Parallel development for potential synergy

- Received national funding support on the project of “pre-clinical research of fully human monoclonal neutralizing antibody and receptor fusion protein targeting COVID-19”

- Submitted patent application on HLX71 (ACE2-Fc receptor fusion protein) and HLX70 (Anti-S1 fully human monoclonal neutralizing antibody)/HLX71 combination therapy targeting COVID-19

<table>
<thead>
<tr>
<th>HLX70 (co-development)</th>
<th>HLX71 (self-development)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monoclonal antibody that targets the Spike protein on the surface of the COVID-19 virus</td>
<td></td>
</tr>
<tr>
<td>✓ IgG1 kappa immunoglobulin, MW of ~145kD</td>
<td></td>
</tr>
<tr>
<td>✓ Proved neutralization activity <em>in vitro</em> and efficacy in preventing and treating virus infection <em>in vivo</em> in mice</td>
<td></td>
</tr>
<tr>
<td>✓ Completed production of clinical sample</td>
<td></td>
</tr>
<tr>
<td>✓ Non-clinical safety study on-going</td>
<td></td>
</tr>
<tr>
<td>Human ACE2-Fc recombinant protein competitively binds to the Spike protein on the surface of the COVID-19 virus</td>
<td></td>
</tr>
<tr>
<td>✓ Glycosylated fusion protein, homodimer with MW of ~218 kDa</td>
<td></td>
</tr>
<tr>
<td>✓ C terminal fusion with IgG1 Fc: extended serum half-life; form dimer which is more similar to natural conformation</td>
<td></td>
</tr>
<tr>
<td>✓ Fully human ACE2 sequence and structure maintain affinity to the virus</td>
<td></td>
</tr>
<tr>
<td>✓ Proven neutralization activity <em>in vitro</em>, study in mice on-going</td>
<td></td>
</tr>
<tr>
<td>✓ Completed production of clinical sample</td>
<td></td>
</tr>
<tr>
<td>✓ Non-clinical safety study on-going</td>
<td></td>
</tr>
</tbody>
</table>
# We Achieved Multiple Major Milestones Since 2020

| Commercialization | • 汉利康®（HLX01, Rituximab）2,000L bioreactor approved, 500mg approved, FL and CLL indications approved  
• HLX02 (Trastuzumab) approved in the EU and China |
|-------------------|--------------------------------------------------|
| **Product Development** | • One phase 3 clinical trial reached primary endpoint  
HLX04 (VEGF) phase 3 clinical trial reached primary endpoint  
• Initiated global parts of two phase 3 clinical trials  
FPI in Turkey for two phase 3 clinical trials of HLX10 + chemo for squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC)  
• Initiated three clinical trials  
C-MET phase 1 clinical trial for solid tumor, HLX10+chemo phase 2 clinical trial for cervical cancer (CC), HLX10+HLX07 phase 2 clinical trial for head & neck squamous cell carcinoma (HNSCC)  
• Received four IND approvals  
HLX11 (HER2), HLX13 (CTLA-4), and HLX14 (RANKL) INDs approved by NMPA, HLX56 (DR4) IND approved by TFDA |
| **BD** | • HLX02 (Trastuzumab) license-out - strategic cooperation with Mabxience  
Reached exclusive development and commercialization license agreements in 3 South American countries for HLX02 (trastuzumab)  
• Cooperation with Sanyou Bio and ZJ Bio-Tech to develop COVID-19 antibody drug  
Proven neutralization activity in vitro and efficacy in preventing and treating virus infection in vivo in mice  
• Cooperation with Accord amended  
HLX02 60mg and 420mg license-out added, royalties increased from 13.5%-25% to 15%-26.5% |
| **Company Development** | • Further capacity increase  
Xuhui facility's commercial production capacity increased to 20,000L; Songjiang Plant 1 started pilot production, construction of Songjiang Plant 2 as planned  
• Initiated STAR Board listing application  
Started on March 30, 2020  
• Growing company size  
1,629 full-time employees (as of June 30, 2020) |
汉利康® (HLX01, Rituximab) Production Capacity Significantly Increased; Two New Indications Approved

2019.02 HLX01(汉利康®) NDA approved by NMPA
-- China’s first approved monoclonal biosimilar based on “Guiding Principles of Biosimilars”

2019.02 Research on HLX01 similarity published on journal of mAbs
-- China’s first published article to evaluate similarity of biosimilars

2019.05 The first prescription written of 汉利康®
-- China’s first commercially launched biosimilar

2020.04 2,000L bioreactor approved for 汉利康®

2020.07 Two new indications approved for 汉利康®: follicular lymphoma and chronic lymphocytic leukemia

Source: EMA, FDA and NMPA websites
## Implementation of Globalization Strategy of 汉曲优® (HLX02, Trastuzumab)

- **First Made-in-China trastuzumab, brand name: 汉曲优® (2020.08)**
- **First “Chinese” trastuzumab approved by the EU, brand name: Zercepac® (2020.07)**
- China’s first trastuzumab developed based on “Guiding Principles of Biosimilars” with NDA accepted by NMPA (2019.04)
- China’s first biosimilar with global multi-center phase 3 clinical trial (2017-2019)

<table>
<thead>
<tr>
<th>Quality Attributes</th>
<th>Methods</th>
<th>HLX Originator</th>
</tr>
</thead>
<tbody>
<tr>
<td>FcRn binding</td>
<td>SPR</td>
<td></td>
</tr>
<tr>
<td>FcγR binding</td>
<td>SPR</td>
<td></td>
</tr>
<tr>
<td>Target binding</td>
<td>Cell based or ELISA binding</td>
<td></td>
</tr>
<tr>
<td>Anti-proliferation potency</td>
<td>Cell based assay</td>
<td></td>
</tr>
<tr>
<td>C1q binding</td>
<td>ELISA</td>
<td></td>
</tr>
<tr>
<td>CDC potency</td>
<td>Cell based CDC assay</td>
<td></td>
</tr>
<tr>
<td>ADCC potency</td>
<td>Cell based ADCC assay</td>
<td></td>
</tr>
<tr>
<td>Apoptosis</td>
<td>Cell based apoptosis assay</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>Stress stability</td>
<td>40℃ R-PM-UPLC-MS/CEX/SEC</td>
</tr>
<tr>
<td>PK in Cynomolgus Monkey</td>
<td></td>
<td>28</td>
</tr>
<tr>
<td>Toxicology - Single Dose</td>
<td></td>
<td>29</td>
</tr>
<tr>
<td>Toxicology - Multiple Doses</td>
<td></td>
<td>30</td>
</tr>
<tr>
<td>Immunogenicity Study in Monkeys</td>
<td></td>
<td>31</td>
</tr>
</tbody>
</table>

### Structural Characterization and Biosimilarity Data Package

<table>
<thead>
<tr>
<th>Category</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Functional Characterization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target and receptor binding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioactivity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-Clinical Data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomized head-to-head comparability studies with biosimilar and originators (EU/China sourced) products to show similarity in terms of PK/PD, quality, safety, and efficacy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data in preparation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Physicochemical Characterization

<table>
<thead>
<tr>
<th>Category</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary structure</td>
<td>Amino acid sequence</td>
<td></td>
</tr>
<tr>
<td>Higher order structure</td>
<td>Secondary and tertiary structure</td>
<td></td>
</tr>
<tr>
<td>General charge</td>
<td>Charge heterogeneity and modifications</td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Size heterogeneity</td>
<td></td>
</tr>
<tr>
<td>LMW, HMW and monomer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Benchmarking EU standard from pre-IND development**

- 2010
- 2015
- 2017
- 2017-2018
- 2019
- 2020.07-08

**Built Global standard manufacturing facility**

**Accord**
- Pan Europe & MENA
- Hong Kong & Macau

**Cipla**
- Australia, NZ, Malaysia, Columbia

**mAbxience**
- Argentina, Uruguay, Paraguay (2020.03)
Significant Progress on Clinical Research

- One phase 3 trial reached primary endpoint, initiated global parts of two phase 3 trials, two phase 2, and one phase 1 trials, four INDs approved

- One phase 3 clinical trial reached primary endpoint:
  ✓ HLX04 (Bevacizumab) (mCRC)

- Initiated global parts of two phase 3 clinical trials:
  ✓ HLX10 (PD-1) + Chemo (sqNSCLC, Turkey)
  ✓ HLX10 (PD-1) + Chemo (ES-SCLC, Turkey)

- Initiated two phase 2 clinical trials:
  ✓ HLX10 (PD-1) + Chemo (CC)
  ✓ HLX10+HLX07 (PD-1+EGFR, HNSCC)

- Initiated one phase 1 clinical trial:
  ✓ HLX55 (c-MET, solid tumor)

- Four INDs approved:
  ✓ HLX11 (Pertuzumab, NMPA)
  ✓ HLX13 (Ipilimumab, NMPA)
  ✓ HLX14 (Denosumab, NMPA)
  ✓ HLX56 (DR4, TFDA)
## Comprehensive Bispecific Antibody Platforms, Multiple Products Expected to File IND in 2021

- Successfully established super-large size (2 x 10^{12}) humanized llama VHH phage library
- Actively advancing 20 preclinical studies on VHH or scFv-based new multi-function antibody/fusion protein projects
- Submitted relevant China and global patent applications, obtained China patent authorization on relevant TIGIT sdAb
- HLX301 (bispecific antibody with TIGIT target) and HLX35 (bispecific antibody with 4-1BB target)
  - Completed preliminary preclinical *in vitro* and *in vivo* studies, and cell line development
  - Further preclinical assessment on-going
  - IND filing expected in 2021

### HLX301: TIGIT x X Bispecific Antibody - T/NK Checkpoint Blockade

<table>
<thead>
<tr>
<th>Target selection</th>
<th>• Both TIGIT and X are expressed on T and NK cells. It belongs to different tumor immune escape pathways</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mode of Action</td>
<td>• Simultaneous blockade of 2 checkpoint molecules. Dual mechanisms limit tumor immune escape</td>
</tr>
<tr>
<td></td>
<td>• Reactivation of exhausted T cells</td>
</tr>
<tr>
<td></td>
<td>• Resistance is expected to be overcome</td>
</tr>
<tr>
<td>Clinical prospects</td>
<td>• Solid tumors</td>
</tr>
<tr>
<td></td>
<td>• It is expected to develop effective biomarkers: T cells and tumor cells</td>
</tr>
<tr>
<td>Competition &amp; Differentiation</td>
<td>• ComboPh2/3 trials ongoing (Genentech, Merck, BMS)</td>
</tr>
<tr>
<td></td>
<td>• First-in-Class</td>
</tr>
<tr>
<td>Preclinical study</td>
<td>• HLX301 has better efficacy than mAb</td>
</tr>
<tr>
<td></td>
<td>• HLX301 has better survival benefits than combo</td>
</tr>
</tbody>
</table>

### HLX35: 4-1BB x TAA Bispecific Antibody

<table>
<thead>
<tr>
<th>Target selection</th>
<th>• Tumor site 4-1BB co-stimulation enhances efficacy and reduce AE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mode of Action</td>
<td>• TAA induces clustering of 4-1BB on T/NK cells for co-stimulation, and enhance co-stimulation signals</td>
</tr>
<tr>
<td>Clinical prospects</td>
<td>• Solid tumors (head and neck, colorectal cancer)</td>
</tr>
<tr>
<td></td>
<td>• Patients with monoclonal antibody resistance</td>
</tr>
<tr>
<td>Competition &amp; Differentiation</td>
<td>• Several 4-1BB mAb trials and other TAAx4-1BB molecules reported</td>
</tr>
<tr>
<td></td>
<td>• First-to-IND potential: no report of xxx x4-1BB by other companies</td>
</tr>
<tr>
<td>Preclinical study</td>
<td>• HLX35 is more efficacious than anti-4-1BB and anti-TAA mAb alone or combination in a colon cancer (LoVo) xenograft model</td>
</tr>
</tbody>
</table>
Henius Has a Comprehensive & Diversified Pipeline with Multiple Products Achieved Progress

<table>
<thead>
<tr>
<th>Product (Reference Drug)</th>
<th>Target</th>
<th>Indication</th>
<th>Pre-Clinical</th>
<th>IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA</th>
<th>Launched</th>
<th>Partners ( Territory)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HX01 (rituximab)</td>
<td>CD20</td>
<td>NHL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer, Genentech</td>
</tr>
<tr>
<td>HX02 (trastuzumab)</td>
<td>HER2</td>
<td>BC/mBC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX03 (adalimumab)</td>
<td>CD20</td>
<td>RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX04 (bevacizumab)</td>
<td>VEGF</td>
<td>mCRC/MSCLL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX05 (velutuximab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX06 (ramucirumab)</td>
<td>VEGFR2</td>
<td>GC/mCRC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX07 (tegafur)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX08 (calicheamicin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX09 (nimotuzumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX10 (pegaptuzumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX11 (ipilimumab)</td>
<td>CTLA-4</td>
<td>Melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX12 (umbralisib)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX13 (demuximab)</td>
<td>RANKL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX14 (aliskizumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX15 (siltuximab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX16 (evoluximab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX17 (erismimab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX18 (nusituzumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX19 (potentimab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX20 (evelumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX21 (mavunatuzumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX22 (marineumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX23 (alevelumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX24 (cotelumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX25 (asulimab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX26 (deltumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX27 (nendanumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX28 (eclipsebiss)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX29 (siltuximab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td>HX30 (potentimab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
</tr>
</tbody>
</table>

**Notes:**

- **Clinical Stage**
  - +Mono: MSH-H/Dr3MM Solid Tumors
  - +Chemo: qSCLC, ES-SCLC, GC, CC
  - *Ligands*

- **Pre-clinical Stage**
  - *Ligands*

- **Potential to be first in class**
  - Tumour-specific target
  - Angiogenesis target
  - Combination therapy
  - Bispecific

- **Promising Stage**
  - Number of Potential NDA
  - Number of Promising Indications

- **Joint Venture/Co-development**
  - Janssen, Janssen
  - Novartis, Novartis

- **Relevant Indications**
  - breast cancer
  - lung cancer

- **Partner Information**
  - Pfizer, Genentech
  - Genentech

- **Additional Information**
  - [1] Approved by the NMPA in February 2019, being the first domestic biosimilar
  - [2] Approved in the EU in July 2020 (EU brand name: Zercepax®); approved in China in August 2020 as the first Chinese mAb biosimilar launched in both China and the EU (China brand name: JIAHUB®).
  - [3] Considered as bio-innovative medicine; the reference product has not yet been approved for the relevant indications
  - [4] FDA for HX03 has been approved by the NMPA
  - [5] Commercialization rights in China have been granted to Shanghai Jingke
  - [6] Commercialization rights in China and certain countries in Southeast, Central and South Asia were obtained
  - [7] Commercialization rights in China were obtained
Combo + Global Strategy of PD-1 Advanced Steadily

- First patient dosed in Turkey for two phase 3 clinical trials of HLX10 (PD-1) + chemo for sqNSCLC and ES-SCLC
- First patient dosed in HLX10(PD-1) + HLX07(EGFR) phase 2 clinical trial for HNSCC

**Combo**
- Combo with current mAbs
  - I/O targets
  - Anti-angiogenesis targets
  - Tumor-specific targets
- Strong self-developed pipeline to create more combo therapies
  - Flexible combo
  - Fast development
  - Cost advantage
- Combo with chemo/radiation

**Global**
- Global multi-center clinical trials
- Enter major markets with global quality
- Enter emerging markets by leveraging FDA/EMA approvals
- Global BD partnership
Domestic & Global Cooperation Further Strengthened

**Domestic cooperation**

- Cooperation with Fosun Kite
  Advanced innovative development of solid tumor cell therapy

- Cooperation with Sanyou Bio and ZJ Bio-Tech to develop COVID-19 antibody drug
  Proven neutralization activity *in vitro* and efficacy in preventing and treating virus infection *in vivo* in mice

**Global cooperation**

- Reached agreement with Mabxience on HLX02
  Exclusive commercial rights of HLX02 for Argentina, Uruguay, and Paraguay

- Cooperation with Accord amended
  HLX02 60mg and 420mg license-out added
  Royalties increased from 13.5%-25% to 15%-26.5%
Commercial Capacity Further Increased, Capacity Planning Implemented Steadily

- Commercial capacity increased from 2,000L in 2019 to current 20,000L
- Support commercial manufacturing for 汉利康® (HLX01, Rituximab), 汉曲优® (HLX02, Trastuzumab), and HLX03 (Adalimumab) to be approved in 2H20
- Received EU GMP certification

Songjiang Plant 1
- Planned capacity of 24,000L
- Started pilot production in 2Q20
- Prepare for production needs before commercial operation of Songjiang Plant 2

Songjiang Plant 2
- Total planned land use of about 33 acres
- Construction started in June 2019
- Completion, and pilot production expected in 2021
The Number of Employees Rapidly Grew with Commercial Team Expanding Quickly

![Bar chart showing the growth in employees from 1H19 to 1H20](chart.png)

- **874** employees in 1H19
- **34%** increase to **1,172** employees in 2019
- **39%** increase to **1,629** employees in 1H20

**Commercial team expanded quickly**

- **53** employees in 2019, which is **4.5%** of total employees
- **310** employees in 1H20, which is **19.0%** of total employees

---

### Personnel Distribution as of June 30, 2020

<table>
<thead>
<tr>
<th>Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D</td>
<td>347</td>
</tr>
<tr>
<td>Clinical</td>
<td>245</td>
</tr>
<tr>
<td>Manufacturing</td>
<td>347</td>
</tr>
<tr>
<td>Quality</td>
<td>223</td>
</tr>
<tr>
<td>Commercial</td>
<td>310</td>
</tr>
<tr>
<td>Administrative</td>
<td>157</td>
</tr>
</tbody>
</table>

Note: as of June 30, 2020
Growing Management Team with Rich Global Experience

Dr. Scott Liu  
Chief Executive Officer, Co-founder  
- 25+ years of experience in biopharmaceutical R&D, manufacturing and quality management  
- Former vice president of UBI, director of quality control at BMS and Amgen  
- “Technical Operations Presidential Award” by BMS  
- Ph.D. in biology at Purdue University and Postdoctoral researcher at Stanford University

Dr. Weidong Jiang  
Chief Science Officer, Co-founder  
- 25+ years of experience in biopharmaceuticals R&D and manufacturing  
- Former director and senior researcher at Vasgene Therapeutics, Applied Molecular Evolution, ChemGenics, Microcide, Eli Lilly and Catalyst Biosciences  
- Ph.D. in natural sciences biology at University of Giessen, postdoctoral training in biology at University of California

Wenjie Zhang  
President  
- 25 years of commercial operation experience in pharmaceutical industry  
- Former business head, business vice president and general manager at Bayer China, Roche China and Amgen China  
- MBA in Yale University and bachelor degree of microbiology in Shandong University

Xinjun Guo  
Board Secretary, Head of Government Affairs and Public Relations

Zidong Zhang  
Chief Financial Officer

Wei Huang  
Head of Manufacturing & Engineering

Cecie Jiang  
Head of Quality Management

Simon Hsu  
Head of Technical Operations & CMC

Ningshu Liu  
Co-Chief Science Officer

Ping Cao  
Head of Business Development

JB Duval  
Head of European Commercial Operation
汉利康® (HLX01, Rituximab) & HLX03 (Adalimumab) – Strong 1H20 Performance Will Continue Strengthening Collaboration with Fosun Pharma in 2H20

- As of 1H20, 汉利康® has gained medical insurance access in 29/30 provinces and completed formal online tendering/procurement filing in 26 provinces
- 2020. 04 汉利康® 2,000L bioreactor was approved
- 汉利康® 500mg formulation was approved by NMPA, providing optimized dose combination for clinical practice

- HLX03 PFS (prefilled syringe) formulation development plan has been confirmed by Manufacturing & Technical Operations departments in 1H20
- RA patient online management system has improved cross-functionally; meanwhile, an online platform “优医学院” is under construction
- In 2H20, Henlius will continue to accelerate the NDA approval process for HLX03
Hansunovo® (HLX02, Trastuzumab) - A New Treatment Choice of Global Quality in Anti-HER2 Space; Approved in the EU in July and in China in August 2020

- HLX02 EMA MAA accepted
- EMA CHMP positive opinion for HLX02
- China approval for HLX02 (汉曲优®)
- EU GMP certification for HLX02
- EU approval for HLX02 (Zercepac®)
汉曲优™ received China NMPA approval in Aug 2020, and will benefit more China HER2+ patients as the first “Made-in-China” trastuzumab.

为HER2阳性乳腺癌/胃癌患者提供更优化的治疗选择
汉曲优® (HLX02, Trastuzumab) - A Strong Commercial Team Is Fully Prepared for Launch Excellence

Characteristics of commercial core leadership team: 1) highly professional; 2) excellent career record; 3) strong leadership

Kurt YU
Marketing & Commercial Operation

Wallis ZENG
Sales Operation

Jun GE
Operation Effectiveness

Xiaoxiao QIAN
Strategic Planning
汉曲优® (HLX02, Trastuzumab) – We Are Officially Launching “Not Leaving Any HER2+ Patient Behind” Flagship Program

Create a win-win ecosystem for patients’ total solutions by collaborating with diverse stakeholders

Collaboration on Physician Education
- Collaborate with medical societies, facilitate at community level
- Empower innovative academic communication platforms and online activities

Collaboration on Testing & Diagnosis
- Collaborate with biomarker testing companies and pathological centers to improve HER2 testing rate and HER+ rate

Collaboration on Patient Affordability
- Collaborate with insurance companies to improve patients’ affordability

Collaboration on Market Access
- Collaborate with the government to promote the research of biosimilar medical insurance policy and payment standards
- Collaborate with commercial companies to maximize market and hospital access

Collaboration on Big Data
- Collaborate with big data companies to strengthen PMS* capabilities and to complement clinical evidence from Chinese patients

Collaboration on Patient Education
- Collaborate with academic societies and patient groups to reduce HCP/patients communication cost and increase adherence

* PMS, post-marketing studies
### 汉曲优® (HLX02, Trastuzumab) – Establish an Efficient and Integrated Commercial Operation System

**Compliance is the ultimate foundation for Henlius’ sustainability of business growth**

<table>
<thead>
<tr>
<th>Market Access</th>
<th>Channel</th>
<th>Marketing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collaborate with academic institutions on biosimilar pricing management research</td>
<td>Establish an optimized pricing system, stabilize product price</td>
<td>Create strategic partnership-enabled ecosystem</td>
</tr>
<tr>
<td>Prepare in advance, quickly complete entering provincial and integrated-planning area medical insurance system</td>
<td>Advocate biosimilars, obtain better bidding/ access outcomes</td>
<td>International top-quality standards for competitive differentiation</td>
</tr>
<tr>
<td>Establish pricing strategy and payment plan that fit mid-/long-term growth</td>
<td></td>
<td>Build a PhIRDA2 Biosimilar Platform, establish industry leadership</td>
</tr>
</tbody>
</table>
汉曲优® (HLX02, Trastuzumab) Sales Operation – Agile, Innovative, Practical, and Compliant

Customer-centric and compliance-based collaboration across departments, corporates, or even industries

- Establish a highly experienced and professional sales management team
- Set up a sales force team consisted of young professionals with entrepreneurship
- Establish an efficient and practical training system
- Set up regional sales operation centers with components of access, marketing, channel, KA, training and SA

- Patient-centric, professionalism-driven
- Establish long-term strategic collaboration with key medical centers/ institutes to accelerate hospital access
- Innovative definition of market range and coverage, especially focusing on the broad market in the initial stage

- Establish provincial mechanism and strengthen RSO’s responsibilities
- Improve sales-operation-relevant policies, systems, and processes, to ensure that sales activities are well regulated and executed effectively
- Go online CRM customer management system

25
Commercial Manufacturing - Three Major Manufacturing Milestones Achieved as Scheduled in 1H20

**Xuhui Facility**
- 2020.04 2,000L bioreactor approved for 汉利康® (HLX01, Rituximab)
- 2020.04 EU GMP approved for HLX02 (Trastuzumab)
- 20,000L manufacturing capacity

**Songjiang Plant 1**
- 2020.04 Commenced pilot production
- Planned capacity of 24,000L
- Prepare to fill in the demand before Songjiang Plant 2 is ready

**Songjiang Plant 2**
- Total area ~33 acres
- Started construction in June 2019
- Completion and pilot production expected in 2021

---

**Wei Huang**
SVP Manufacturing & Engineering
Past work experience with Newa, REG, Fluor, Baxter

**Simon Hsu**
SVP Technical Operations & CMC
Past work experience with Pieris, Takeda, AstraZeneca, Alexion

**Cecie Jiang**
SVP Quality Management
Past work experience with Twib, Aphen, Boehringer Ingelheim
Henlius Three Manufacturing Bases Are Steadily Upgrading or Constructing

Xuhui Facility

- Successful completion of 汉利康® (HLX01, Rituximab) 500L to 2,000L commercial production capacity
- Total capacity increased to 20,000L
- Explore multiple options to increase manufacturing capacity

Songjiang Plant 1

- Songjiang Plant 1 pilot plant construction has completed; continuous production plant is under construction
- Songjiang Plant 1 entered GMP production in 2Q20, starting manufacturing products for clinical studies

Songjiang Plant 2

- Songjiang Plant 2 Stage 1 construction completed; two manufacturing buildings’ structural roof-sealing completed in Aug 2020
- DS plant design changed to hybrid of single-use and stainless steel, in the purpose of increasing production capacity and reducing COGS, which would be set the foundation of 2nd and 3rd generation technology
Financial Review

Zidong Zhang – CFO

© 2020 Henlius
## Significant Sales Growth in 1H20;
~43% Growth in R&D Expenditure; Cash and Cash Equivalents of ¥1.15B

<table>
<thead>
<tr>
<th>Revenue</th>
<th>• RMB 110.4M sales from main operating business in 1H20, mainly from profit sharing of our core product 汉利康®</th>
</tr>
</thead>
</table>
| R&D expenditure | • RMB 756.9M R&D expenditure in 1H20 (+43.2% vs 1H19)  
• Among which RMB 393.0M expensed (51.9%), RMB 363.9M capitalized (48.1%) |
| Financial status | • As of June 30, 2020, current assets of RMB 1,671.5M mainly include:  
  ✓ Cash & cash equivalents of RMB 1,146.4M  
  ✓ Inventories of RMB 165.0M  
  ✓ Prepayments, deposits and other receivables of RMB 264.9M  
• As of June 30, 2020, total bank borrowings were RMB 403.4M |
Reliable Quality | Affordable Innovation